EDOXABAN

Course overview

EDOXABAN BELONGS TO THE CLASS OF DIRECT ORAL ANTICOAGULANTS (DOACS) AND IS USED FOR THE TREATMENT OF PULMONARY EMBOLISM (PE), DEEP VENOUS THROMBOSIS (DVT), AND TO REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF). THIS DRUG EXERTS ITS THERAPEUTIC EFFECTS BY INHIBITING FACTOR XA DIRECTLY, SELECTIVELY, AND REVERSIBLY AS PART OF ITS MECHANISM OF ACTION. IN CONTRAST TO THE WIDELY USED ANTICOAGULANT WARFARIN, EDOXABAN OFFERS THE ADVANTAGE OF FEWER MONITORING REQUIREMENTS, LOWER RISK OF SUBSTANTIAL BLEEDING, AND INFREQUENT DRUG INTERACTIONS.THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM OF ACTION, AND CONTRAINDICATIONS FOR EDOXABAN AS A VALUABLE AGENT IN TREATING AND MANAGING THROMBOEMBOLIC EVENTS. THIS ACTIVITY ALSO HIGHLIGHTS THE ADVERSE EVENT PROFILE AND OTHER CRUCIAL CONSIDERATIONS RELATED TO EDOXABAN THAT ARE ESSENTIAL FOR HEALTHCARE PROFESSIONALS INVOLVED IN CARING FOR PATIENTS WITH PE, DVT, AND NVAF.